Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 55,500 shares, agrowthof48.4% from the July 15th total of 37,400 shares. Based on an average daily volume of 115,300 shares, the short-interest ratio is currently 0.5 days. Approximately0.1% of the shares of the stock are short sold. Approximately0.1% of the shares of the stock are short sold. Based on an average daily volume of 115,300 shares, the short-interest ratio is currently 0.5 days.

Analysts Set New Price Targets

Separately, HC Wainwright upgraded shares of Entera Bio to a "strong-buy" rating in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the company has an average rating of "Strong Buy" and an average price target of $10.00.

Entera Bio Price Performance

Shares of ENTX stock traded down $0.01 during trading hours on Friday, reaching $1.94. 35,204 shares of the company were exchanged, compared to its average volume of 290,257. Entera Bio has a fifty-two week low of $1.5006 and a fifty-two week high of $2.79. The stock's fifty day moving average is $1.94 and its two-hundred day moving average is $1.97. The company has a market cap of $88.58 million, a price-to-earnings ratio of -7.46 and a beta of 1.52.

Entera Bio (NASDAQ:ENTX - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.05. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 77.75%. On average, research analysts anticipate that Entera Bio will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Entera Bio

Large investors have recently bought and sold shares of the business. HighTower Advisors LLC lifted its holdings in Entera Bio by 53.3% in the first quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock valued at $31,000 after buying an additional 6,310 shares during the period. Bessemer Group Inc. acquired a new position in Entera Bio in the second quarter valued at approximately $268,000. Northern Trust Corp acquired a new position in Entera Bio in the fourth quarter valued at approximately $450,000. Parkman Healthcare Partners LLC increased its stake in Entera Bio by 6.3% in the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock valued at $747,000 after purchasing an additional 25,900 shares in the last quarter. Finally, Knoll Capital Management LLC increased its stake in Entera Bio by 51.5% in the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after purchasing an additional 2,000,000 shares in the last quarter. 14.11% of the stock is currently owned by institutional investors and hedge funds.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.